<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305041</url>
  </required_header>
  <id_info>
    <org_study_id>3475-02A</org_study_id>
    <secondary_id>2019-003956-35</secondary_id>
    <secondary_id>MK-3475-02A</secondary_id>
    <secondary_id>KEYMAKER-U02</secondary_id>
    <nct_id>NCT04305041</nct_id>
  </id_info>
  <brief_title>Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)</brief_title>
  <official_title>A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Substudy 02A is part of a larger research study that is testing experimental treatments for&#xD;
      melanoma, a type of skin cancer. The larger study is the umbrella study.&#xD;
&#xD;
      The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment&#xD;
      arms in participants with PD-1 refractory melanoma to identify the investigational agent(s)&#xD;
      that, when used in combination, are superior to the current treatment options/historical&#xD;
      control available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2020</start_date>
  <completion_date type="Anticipated">April 3, 2030</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2030</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who experience an adverse event (AE)</measure>
    <time_frame>Up to ~28 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience an AE will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who discontinue study treatment due to an AE</measure>
    <time_frame>Up to ~24 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study treatment due to an AE will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>ORR is defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per RECIST 1.1</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>For participants in the analysis population who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 as assessed by BICR. RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + Quavonlimab + Vibostolimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pembrolizumab intravenously (IV) plus quavonlimab IV plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab + Quavonlimab + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pembrolizumab IV plus quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered via IV infusion at a specified dose on specified days</description>
    <arm_group_label>Pembrolizumab + Quavonlimab + Lenvatinib</arm_group_label>
    <arm_group_label>Pembrolizumab + Quavonlimab + Vibostolimab</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quavonlimab</intervention_name>
    <description>Administered via IV infusion at a specified dose on specified days</description>
    <arm_group_label>Pembrolizumab + Quavonlimab + Lenvatinib</arm_group_label>
    <arm_group_label>Pembrolizumab + Quavonlimab + Vibostolimab</arm_group_label>
    <other_name>MK-1308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vibostolimab</intervention_name>
    <description>Administered via IV infusion at a specified dose on specified days</description>
    <arm_group_label>Pembrolizumab + Quavonlimab + Vibostolimab</arm_group_label>
    <other_name>MK-7684</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Administered via oral capsules at a specified dose on specified days</description>
    <arm_group_label>Pembrolizumab + Quavonlimab + Lenvatinib</arm_group_label>
    <other_name>MK-7902</other_name>
    <other_name>LENVIMA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has histologically or cytologically confirmed melanoma&#xD;
&#xD;
          -  Has unresectable Stage III or Stage IV melanoma, not amenable to local therapy&#xD;
&#xD;
          -  Has progressed on treatment with an anti-PD-1/L1 monoclonal antibody (mAb)&#xD;
             administered either as monotherapy, or in combination with other therapies&#xD;
&#xD;
          -  Has submitted prestudy imaging&#xD;
&#xD;
          -  Has not received more than 3 lines of therapy for their advanced melanoma&#xD;
&#xD;
          -  Has provided a tumor biopsy&#xD;
&#xD;
          -  Male participants who receive lenvatinib are abstinent from heterosexual intercourse&#xD;
             or agree to use contraception during the intervention period and for at least 7 days&#xD;
             after the last dose of lenvatinib; for male participants who only receive&#xD;
             pembrolizumab, quavonlimab, vibostolimab, or a combination, no contraception measures&#xD;
             are needed&#xD;
&#xD;
          -  Female participant are not pregnant or breastfeeding and are either not a woman of&#xD;
             child-bearing potential (WOCBP) OR use a contraceptive method that is highly effective&#xD;
             or are abstinent from heterosexual intercourse during the intervention period and for&#xD;
             at least 120 days after the last dose of pembrolizumab, quavonlimab, vibostolimab or&#xD;
             30 days after the last dose of lenvatinib, whichever occurs last&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
          -  Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less&#xD;
             (except alopecia)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 7&#xD;
             days before the first dose of study intervention&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment&#xD;
             within the past 2 years&#xD;
&#xD;
          -  Has known central nervous system (CNS) metastases and/or carcinomatous meningitis&#xD;
&#xD;
          -  Has ocular or mucosal melanoma&#xD;
&#xD;
          -  Has known hypersensitivity including previous clinically significant hypersensitivity&#xD;
             reaction to treatment with another mAb&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in the past 2&#xD;
             years&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has known history of human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Has known history of hepatitis B&#xD;
&#xD;
          -  Has a history of (noninfectious) pneumonitis&#xD;
&#xD;
          -  Has a history of active tuberculosis (TB)&#xD;
&#xD;
          -  Has received prior systemic anticancer therapy within 4 weeks prior to randomization&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks of first dose of study intervention&#xD;
&#xD;
          -  Has had major surgery &lt;3 weeks prior to first dose of study intervention&#xD;
&#xD;
          -  Has received a live vaccine within 30 days before the first dose of study intervention&#xD;
&#xD;
          -  Has participated in a study of an investigational agent within 4 weeks prior to the&#xD;
             first dose of study intervention&#xD;
&#xD;
          -  Has had an allogeneic tissue/solid organ transplant&#xD;
&#xD;
          -  Has a pre-existing Grade ≥3 gastrointestinal fistula or nongastrointestinal fistula&#xD;
&#xD;
          -  Has radiographic evidence of encasement of invasion of major blood vessel or of&#xD;
             intratumoral cavitation&#xD;
&#xD;
          -  Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the&#xD;
             first dose of study intervention&#xD;
&#xD;
          -  Has clinically significant cardiovascular disease within 12 months from first dose of&#xD;
             study intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute ( Site 1009)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>999-999-9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology &amp; Oncology ( Site 1004)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-794-6892</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Saint John's Health Center ( Site 1010)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-582-7455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Anschutz Cancer Pavilion ( Site 1012)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-848-0442</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1022)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>999-999-9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Clinical Cancer Center ( Site 1002)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>999-999-9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute ( Site 1005)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-660-9671</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University ( Site 1013)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Abramson Cancer Center ( Site 1008)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-316-5151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Cancer Center - East Campus ( Site 1014)</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>901-683-0055</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center ( Site 1006)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>999-999-9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute ( Site 1011)</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>571-472-0631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle-Medical Oncology ( Site 1404)</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61249211561</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia ( Site 1402)</name>
      <address>
        <city>Wollstonecraft</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61299117321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tasman Oncology Research Pty Ltd ( Site 1403)</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61 7 5613 2480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital ( Site 1401)</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61861522222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Timone ( Site 1103)</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhone</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33491388591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre ( Site 1108)</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556794705</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud ( Site 1105)</name>
      <address>
        <city>Toulouse cedex 9</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33531155101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud ( Site 1102)</name>
      <address>
        <city>Pierre Benite</city>
        <state>Rhone</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33478861628</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy ( Site 1101)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142114210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.P.H. Paris, Hopital Saint Louis ( Site 1107)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142499595</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HaEmek Medical Center ( Site 1703)</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97246495723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus-Oncology ( Site 1704)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247776700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Jerusalem ( Site 1702)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226776781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 1701)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235304907</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1399)</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00390223902557</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia ( Site 1301)</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390294379224</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione Pascale ( Site 1302)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390815903431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Le Scotte - A.O. Senese ( Site 1377)</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00390577586335</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41213140155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zuerich ( Site 1601)</name>
      <address>
        <city>Zuerich Flughafen</city>
        <state>Zurich</state>
        <zip>8058</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41442552588</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>receptor tyrosine kinase inhibitor</keyword>
  <keyword>programmed cell death 1 (PD-1, PD1)</keyword>
  <keyword>programmed cell death ligand 1 (PD-L1, PDL1)</keyword>
  <keyword>T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine receptor motif domains (TIGIT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

